KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aquestive Therapeutics (AQST) Shares Outstanding (Diluted Average) (2020 - 2025)

Aquestive Therapeutics (AQST) has 6 years of Shares Outstanding (Diluted Average) data on record, last reported at $106.9 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 23.29% year-over-year to $106.9 million; the TTM value through Dec 2025 reached $106.9 million, up 23.29%, while the annual FY2025 figure was $106.9 million, 23.29% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $106.9 million in Q4 2025 per AQST's latest filing, up from $101.9 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $106.9 million in Q4 2025 and bottomed at $35.6 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $66.1 million, with a median of $61.4 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Diluted Average): skyrocketed 77.96% in 2023, then decreased 0.24% in 2024.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $38.1 million in 2021, then increased by 27.99% to $48.7 million in 2022, then increased by 25.69% to $61.3 million in 2023, then soared by 41.58% to $86.7 million in 2024, then rose by 23.29% to $106.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Diluted Average) were $106.9 million in Q4 2025, $101.9 million in Q3 2025, and $97.4 million in Q2 2025.